Proportion with zero bleeds · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people without inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors
1 finding from 1 review
Proportion with zero bleeds · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people without inhibitors
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics may leads to lower pulmonary exacerbations: frequency of one or more hospital admissions compared with placebo (low certainty).
1 finding from 1 review
Quality of life: lost school or working days · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in survival: number of deaths compared with placebo (low certainty).
1 finding from 1 review
Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found